Fact CheckerSign in

NCT04242823Active, not recruiting

Primary HPV-based Cervical Cancer Screening Algorithms in Botswana

Performance of Two-stage Cervical Cancer Screening Algorithms Using Primary High-risk Human Papillomavirus Testing in Botswana

Source: ClinicalTrials.gov · Last updated 27 Apr 2026

Brief summary (registry, in English)

Primary high-risk human papillomavirus (HPV) testing has become first line screening for cervical cancer in high-income countries. The feasibility of this approach in low- and middle-income countries (LMICs) is less clear, as is the role of HPV testing among women living with human immunodeficiency virus (HIV). The proposed study seeks to evaluate the accuracy of cervical cancer screening algorithms using primary HPV testing followed by various forms of visual evaluation, including visual inspection with acetic acid (VIA), colposcopy and HPV genotype restriction for the detection of high-grade cervical dysplasia, using histology as the gold standard. We will validate the AmpFire Assay for HPV self-sampling in our setting. We will evaluate optimal screening intervals in women living with HIV (WLHIV) in an HPV-based cervical cancer screening program and compare triage strategies for positive HPV results at WHO recommended screening intervals for WLHIV. We also seek to understand in-depth the attitudes, acceptability and preferences regarding cervical cancer screening, HPV testing, and self-sampling, for women in Botswana through interviews of a sub-set of women recruited for the cervical cancer screening study. Finally, we will analyze the cost of two-stage cervical cancer screening algorithms using high-risk HPV testing in Botswana.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
3000 (actual)
First submitted
23 Jan 2020
Start date
22 Feb 2021
Primary completion date
1 Feb 2026
Lead sponsor
Beth Israel Deaconess Medical Center
NCT number
NCT04242823

What you commit to

  • Study type: Interventional
  • Participants enrolled: 3000
  • From 22 Feb 2021 to the primary completion date, 1 Feb 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous hysterectomy
  • Previous diagnosis of cervical cancer

Other illness

  • Currently pregnant (as diagnostic procedures for cervical cancer are often deferred during pregnancy)

Who the study is looking for

  • Cis-gender female or transgender male (must have a cervix)
  • ≥25 years of age
  • Competent to understand study procedures and give informed consent.

Age in the registry: 25 years to 100 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Bamalete Lutheran Hospital
Coordinator of this site? Confirm its status
RamotswaBotswanaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.